Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma

Disialoganglioside (GD2)‐specific chimeric antigen receptor (CAR)‐T cells (GD2‐CAR‐T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. However, the effectiveness of immunotherapy using these cells is limited, and requires improvement....

Descripción completa

Detalles Bibliográficos
Autores principales: Tomida, Akimasa, Yagyu, Shigeki, Nakamura, Kayoko, Kubo, Hiroshi, Yamashima, Kumiko, Nakazawa, Yozo, Hosoi, Hajime, Iehara, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486218/
https://www.ncbi.nlm.nih.gov/pubmed/34382720
http://dx.doi.org/10.1111/cas.15074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486218/
https://www.ncbi.nlm.nih.gov/pubmed/34382720
http://dx.doi.org/10.1111/cas.15074

Ejemplares similares